The safety and efficacy of a single dose (500 mg or 1 g) of intravenous magnesium sulfate in neuropathic pain poorly responsive to strong opioid analgesics in patients with cancer

Journal of Pain and Symptom Management

Volumn 19, Issue 1, 2000, Pages 35-39

  Crosby, Vincent ^a   Wilcock, Andrew ^a   Corcoran, Ray ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Cancer; Magnesium sulfate; Neuropathic pain

Indexed keywords

MAGNESIUM SULFATE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUMBOSACRAL PLEXUS; MALE;

AGED; ANALGESICS; ANALGESICS, OPIOID; DRUG RESISTANCE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MAGNESIUM SULFATE; MALE; MIDDLE AGED; NEOPLASMS; NEURALGIA; SAFETY;

EID: 0033983345     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(99)00135-9     Document Type: Article

References (14)

1. Zech DFJ, Grond S, Lynch J, Hertel D, Lehman KA. Validation of world health organization guidelines for cancer pain relief: A 10-year prospective study. Pain 1995;63:65-76.
2. Cherny NI, Thaler HT, Freidlander-Klar C, Lapin J, Foley KM, Houd R, Portenoy RK. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: A combined analysis of controlled, single dose studies. Neurology 1994;44:857-861.
3. Jaded AR, Carroll D, Glynn CJ, Moore RA, McQuay HJ. Morphine responsiveness of chronic pain: Double blind randomised crossover study with patient controlled analgesia. Lancet 1992;339:1367-1371.
4. Martin LA, Hagen NA. Neuropathic pain in cancer patients: Mechanisms, syndromes and clinical controversies. J Pain Symptom Manage 1997;14:99-117.
5. Luczak J, Dickenson AH, Kotlinska-Lemieszek A. The role of ketamine, an NMDA receptor antagonist, in the management of pain. Progress Palliat Care 1995;3:127-134.
6. Dickenson AH. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 1990;11:307-309.
7. 2+ like selective antagonism of excitatory amino acid induced responses by alpha-epsilon-diaminopimelic acid, d-alpha-aminoadipate and HA-996 in isolated spinal cord of frog and immature rat. Brain Res 1978;148:536-542.
8. Xiao WH, Bennett GJ. Magnesium suppresses neuropathic pain responses in rats via a spinal site of action. Brain Res 1994;666:168-172.
9. Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulfate relieves migraine attacks in patients with low serum ionised magnesium levels: A pilot study. Clin Sci 1995;89:633-636.
10. Tramer MR, Schneider J, Marti RA, Rifat K. Role of magnesium sulfate in postoperative analgesia. Anesthesiology 1996;84:340-347.
11. Felsby S, Neilson J, Arendt-Neilson L, Jensen TS. NMDA receptor blockade in chronic neuropathic pain: A comparison of ketamine and magnesium chloride. Pain 1995;64:283-291.
12. Mann CK, Yoe JH. Spectrophotometric determination of magnesium with 1-azo-2-hydroxy-3-(2,4 dimethylcarboxanilido)-naphthalene-1-(2-hydroxybenzene). Anal Chim Acta 1957;16:155-160.
13. Durlach J, Durlach V, Bac P, Bar M, Guiet-Bara A. Magnesium and therapeutics. Magnes Res 1994;7:312-328.
14. Verdugo RJ, Ochoa JL. Placebo response in chronic causalgiform, "neuropathic" pain patients: Study and review. Pain Rev 1994;1:33-46.